Value-Based Cancer Care Special Issues

All previous special issues and supplements of Value-Based Cancer Care are available here. Browse the digital archive below or use the search page to find a specific article you're looking for.

Highlights from the Latest Special Issue:

AUGTYRO (Repotrectinib) for the Treatment of ROS1-Positive Non-Small Cell Lung Cancer

We are delighted to announce the release of our next issue of Clinical Trials to Clinical Practice. This piece provides expert insights from Vamsi Velcheti, MD, MBA, FASCO, FACP, FCCP, regarding the outcomes of patients with ROS1-positive non–small cell lung cancer treated with AUGTYRO in the phase 1-2 TRIDENT-1 study.

Read Article ›

Value-Based Cancer Care Special Issues By Year

• 2025
  

  AUGTYRO (Repotrectinib) for the Treatment of ROS1-Positive Non-Small Cell Lung Cancer

  Read Issue

• 2024
  

  Real-World Uptake and Utilization Patterns of Biosimilars in Clinical Practice

  Read Issue

• 2023
  

  Faculty Perspectives Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine

  Read Issue

• 2022
  

  2022 Year in Review - Multiple Myeloma

  Read Issue

  

  Faculty Perspectives: Optimizing Clinical Outcomes and Value-Based Management in Multiple Myeloma—The Role of Isatuximab

  Read Issue

  

  Interview With the Innovators Current Approach to the Disease Journey of Patients with Relapsed or Refractory Follicular Lymphoma: Focus on the Key Manifestations, Risk Stratification, and Management Patterns

  Read Issue

  

  Faculty Perspectives: The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management

  Read Issue

• 2021
  

  MOA magnifier: The Important Role of YERVOY® (ipilimumab) in Combination with OPDIVO® (nivolumab)

  Read Issue

  

  Faculty Perspectives: Preventing and Managing Skeletal-Related Events in Cancer Patients with Bone Metastases and Multiple Myeloma

  Read Issue

• 2020
  

  Managing CCA in the Setting of COVID-19

  Read Issue

• 2019
  

  December 2019 Highlights from the First Annual Cholangiocarcinoma Summit

  Read Issue

  

  2019 Fourth Annual Oncology Guide to New FDA Approvals

  Read Issue

• 2018
  

  2018 Third Annual Oncology Guide to New FDA Approvals

  Read Issue

  

  Mechanism of Pathway: Considerations of Cytogenetic and Molecular Mutation Status for Patients with Acute Myeloid Leukemia: A Deeper Look at the Role of Diagnosticand Ongoing Testing Across the Care Continuum

  Read Issue

• 2017
  

  June 2017, Vol 8, No 3, Supplement 2: The Evolution of Chemotherapy-Induced Nausea and Vomiting Management: Challenges and Opportunities

  Read Issue

  

  Front-Line Treatment of Patients with Advanced Hodgkin Lymphoma

  Read Issue

  

  February 2017, Vol 8, No 1, Supplement 1: Balancing Innovation and Value in Cancer Care: Spotlight on Non-Small-Cell Lung Cancer Treatment

  Read Issue

• 2016
  

  Highlights from Best Practices in Lung Cancer Navigation Summit

  Read Issue

  

  Consolidation Therapy After ASCT in Hodgkin Lymphoma: Why and Who to Treat

  Read Issue

  

  Mechanism of Action Magnifier – 2016 Desk Reference

  Read Issue

  

  Mechanism of Action: Novel Mechanisms in Lung Cancer

  Read Issue

• 2015
  

  Dx Profiler: Can Metastatic Cancer with Diagnostic Ambiguity Be Treated Based on Mutational Status Alone?

  Read Issue

  

  Mechanism of Pathway: Phosphatidylserine, an Immune-Modulating Checkpoint, Ushers in the Next Wave of Immuno-Oncology Targets

  Read Issue

• 2014
  

  Mechanism of Action: Novel Mechanisms in CINV Treatment

  Read Issue

  

  Mechanism of Pathway: The Promise of PD-1 Pathway Blockade in the Treatment of Metastatic Cancer

  Read Issue

• 2013
  

  Mechanism of Action: Key Advances in Hematology Oncology

  Read Issue